FOR US HEALTH CARE PROFESSIONALS ONLY
FILTER
Filter by
Year
Therapeutic Area
Attention-Deficit/ Hyperactivity DisorderParkinson's DiseaseProduct
APOKYN® (apomorphine hydrochloride injection)GOCOVRI® (amantadine) extended-release capsulesQELBREE® (viloxazine)ONAPGO™ (apomorphine hydrochloride), for subcutaneous infusionPipeline
SPN-817 (Focal onset seizures, including resistant focal onset seizures)SPN-820/821 (Treatment-resistant depression)Poster content may not be subject to peer review and should be considered a preview of emerging data. Results may be subject to change upon final analysis. Posters may not be cited as reference sources. Poster data are time limited, and posters are subject to removal after publication or at the sponsor’s discretion.
Publications may contain data outside the approved product labeling. Supernus Pharmaceuticals does not support the use of its products in a manner that is not consistent with the product labeling.
